BioCentury
ARTICLE | Financial News

Arch leads Nohla's $45M series B

May 15, 2018 8:54 PM UTC

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and Celgene Corp. (NASDAQ:CELG) and previous investors 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners.

Nohla’s lead candidate, dilanubicel (NLA101), is in a Phase IIb trial to treat patients with hematologic malignancies undergoing allogeneic transplant and a Phase II trial to treat acute myelogenous leukemia patients with chemotherapy-induced myelosuppression following high-dose chemotherapy. Nohla spokesperson Jim DeNike told BioCentury the company expects top-line data from the trials by the end of this year and in 2H19, respectively...